VanEck Ethereum ETF VanEck Ethereum ETF (BATS: ETHV)

에 대한 최신 뉴스 VanEck Ethereum ETF VanEck Ethereum ETF (BATS:ETHV)

The Trust is a passive investment vehicle that does not seek to pursue any investment strategy beyond tracking the price of ETH

VanEck Ethereum ETF

Bitcoin and Ethereum Photo by Marisha on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

ETFs

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

ETHA

ETHV

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

IBIT

비트코인(CRYPTO: BTC)과 이더리움(CRYPTO: ETH) 현물 ETF는 지난 4일 동안 각각 32억 6천만 달러와 7,443만 달러의 유입을 기록했다.

비트코인·이더리움 ETF, 시장 변동성과 정책 불확실성에도 기록적 자금 유입 발생

VanEck Ethereum ETF VanEck Ethereum ETF

WIIM

VRME

VerifyMe shares are trading lower following a Q1 revenue miss.

HYFM

Hydrofarm Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Oppenheimer analyst Kristen Owen maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Outperform and raises the price target from $33 to $40.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Mosaic, Raises Price Target to $40

NPWR

NET Power shares are trading lower after the company reported a year-over-year decrease in Q1 EPS results.

PRSO

Peraso shares are trading lower after the company issued Q2 sales guidance below estimates.

Oppenheimer analyst Andreas Argyrides maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Outperform and lowers the price target from $155 to $90.

KRRO

Oppenheimer Maintains Outperform on Korro Bio, Lowers Price Target to $90

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1.png" alt="" class="wp-image-12845" style="width:902px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The American vaping company with strong Chinese ties reported its revenue fell 12.7% in the three months to March, as it rushes to set up a new manufacturing facility in Malaysia
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Ispire's revenue fell and its loss widened in its latest fiscal quarter, as it overhauled its operation to reduce exposure to the U.S.-China trade war</li>
<li>The company is rushing to open a new factory in Malaysia, mirroring similar moves by other vaping companies to diversify their production away from China</li>
</ul>
A landmark trade deal between the U.S. and China lit a fire under U.S.-traded Chinese stocks on Monday, but you would never know from looking at shares of&nbsp;Ispire Technology Inc.&nbsp;(ISPR.US). Perhaps the vaping company would like it that way, since it's trying hard to convince investors it's a Los Angeles-based, U.S. entity, despite its strong China ties.
The reality is that Ispire is still quite reliant on China, which currently supplies most of its vaping hardware from its self-owned subsidiary in the Southern boomtown of Shenzhen. But the company is moving quickly to reduce those China ties, and provided a detailed update of its plans to move a major portion of its production to a new facility in Malaysia in its&nbsp;<a href="https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-third-quarter-2025-302451490.html">latest quarterly results</a>&nbsp;announced on Monday.
Co-CEO Michael Wang also detailed a broader scramble by vaping product makers in general to move production out of China to lower exposure to potential U.S. tariffs in the ongoing trade war. He said that movement includes a couple of Ispire's competitors trying to set up factories in Vietnam, while others move to Indonesia.
"In this industry, literally 99.99% of vaping devices up to, say, two years ago were made in China," Wang said on Ispire's earnings call to discuss the latest results for the three months to March, its third fiscal quarter. "Today, there is a little bit of diversification in terms of country of origin, but still well over 90% of products are made in China."
Trade wars aside, Ispire is also being dogged by its own internal issues, which may explain why its stock fell 3% on Monday after it released its latest report. That contrasts sharply with a 3.4% rally for the MSCI China Index, as investors cheered a sharp reduction in tariffs imposed by the U.S. and China on each other's products for 90 days while they try to hammer out details of a new, longer-term trade deal.
Ispire's issues include declining revenue, high accounts receivable, margins that are well below its global peers, and ongoing losses that are only getting larger. Adding to the problems are earlier company hype about the potential of the cannabis vaping market, which led it to predict that sales of related products could help to drive its overall revenue to $1 billion by 2027 and $2 billion by 2029.
Such astronomic heights would require breakneck revenue growth, which was hardly what Ispire delivered in its latest results. Instead, the company reported its revenue fell 12.7% in the three months to March to $26.2 million from $30 million a year earlier – making the $1 billion revenue forecast look almost laughable.
The company provided a few updates on its cannabis business on its earnings call, including the launch of a new device called Sprout in a new partnership with a company called Raw Garden. But, probably wisely, it refrained from providing any inflated revenue forecasts for the business. Instead, Wang characterized his company as being in a "restructuring and manufacturing transitional period," which includes moving some of its manufacturing to Malaysia and also weaning itself from lower-quality customers who were driving up its accounts receivable to dangerously high levels.
<h4 class="wp-block-heading">Back to basics</h4>
Ispire has repeatedly drawn attention to its growing accounts receivables in earlier reports, showing both the company and investment community were worried about the trend. Against that backdrop, it said it recorded a milestone in the latest quarter by reducing its accounts receivables for the first time in its history. Specifically, it said the figure dropped to $60.4 million by the end of March from $67.7 million three months earlier.
We should point out the newest amount is still more than double the company's latest quarterly revenue. Still, the reduction shows Ispire realizes it can't just sell products to deadbeat customers who never pay their bills. Such deadbeats are eating into the company's cash, which plunged about 40% to $23.5 million at the end of March from $39.5 million a year ago.
As we've previously noted, the other focus for Ispire was its ongoing efforts to set up a new production facility in Malaysia to lower its geopolitical risk. On that front, Wang said Ispire recently received an interim license to manufacture nicotine products in Malaysia and anticipates getting a final license in the next few months. He added the facility is designed to eventually house up to 80 production lines.
"We have made significant strides as we are transitioning our manufacturing to&nbsp;Malaysia, effectively de-risking our production strategy for the current geopolitical climate," Wang said. "During the third fiscal quarter, in an effort to further streamline our operations and increase margins, we moved a number of our daily functions to our Malaysian campus, which we anticipate will reduce our operating expenses by&nbsp;$8 million&nbsp;annually."
Growing expenses are indeed a problem for the company. Its gross profit fell 21.3% during the quarter, dragging down its gross margin to 18.2% from 20.4%. Both margin figures are well behind rival&nbsp;RLX's&nbsp;(RLX.US) gross margin of 27.0% in last year's fourth quarter, showing just how much work Ispire needs to do to become more efficient. At the same time, Ispire's operating expenses rose 30.5% year-on-year to $15.4 million in the latest quarter, as it blamed factors like stock-based compensation, bad-debt expense and one-off severance costs.
That combination of falling revenue and rising expenses caused Ispire's net loss to widen to $10.9 million in the latest quarter from $5.9 million a year earlier.
The company held out a glimmer of hope for investors by saying that benefits from its restructuring in North America – which accounts for about a third of sales – will start to show up in its next quarterly report for the three months to June.
Investors seem to be losing patience with the company, with its shares down about 50% over the last year to trade at just under $3 – less than half their IPO price of $7 in 2023. At that level the stock now trades at depressed price-to-sales (P/S) ratio of just 1.14, a small fraction of the 6.94 for RLX, and a similar 6.90 for Hong Kong-listed rival&nbsp;Smoore International&nbsp;(6969.HK).

Equities

Opinion

Markets

Trading Ideas

This Cannabis Stock Sits Out The Rally Sparked By US-China Deal

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed shares are trading higher after the company reported better-than-expected Q1 sales results.

VCIG

VCI Global shares are trading higher following a year-over-year increase in FY24 sales results.

Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform and lowers the price target from $15 to $9.

PRQR

Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

KPTI

Karyopharm Therapeutics shares are trading lower after several firms cut their respective price targets on the stock.

MASS

908 Devices shares are trading lower following a Q1 sales miss and FY25 issued sales guidance below estimates.

ELSE

Electro-Sensors shares are trading higher following Q1 reported financial results.

<a href="https://truthsocial.com/@realDonaldTrump/posts/114501759958997511" title="https://truthsocial.com/@realDonaldTrump/posts/114501759958997511">https://truthsocial.com/@realDonaldTrump/posts/114501759958997511</a>

Macro Economic Events

Economics

Federal Reserve

President Trump Posts On Truth Social "No Inflation, and Prices of Gasoline, Energy, Groceries, and practically everything else, are DOWN!!! THE FED must lower the RATE, like Europe and China have done. What is wrong with Too Late Powell? Not fair to America, which is ready to blossom? Just let it all happen, it will be a beautiful thing!"

Natural Gas Services Group shares are trading higher after the company reported better-than-expected Q1 financial results.

May 13, 2025
RIYADH
Qualcomm Technologies, Inc. and Aramco Digital announced their intent to enter into a strategic collaboration to develop, deploy and commercialize state-of-the-art edge AI industrial IoT technologies and solutions, which will drive the digital transformation of key industries in the Kingdom of Saudi Arabia. The collaboration also covers the development of AI industrial use-cases and service offerings.
Aramco Digital will aim to develop and commercialize a range of advanced edge AI industrial devices and end-to-end solutions powered by products and services from Qualcomm Technologies. These solutions will help meet the specific requirements of various industry sectors in the Kingdom, and are designed to increase efficiency and productivity, enhance safety and sustainability, and enable new innovations in industrial-based services, from worker assistants to predictive maintenance, visual anomaly detection, asset management and more.
The collaboration is intended to utilize Aramco Digital's 450 MHz 5G industrial network to connect intelligent edge devices powered by solutions from Qualcomm Technologies-including smartphones, rugged industrial devices, robots, drones, cameras, sensors, and other IoT devices. Aramco Digital and Qualcomm Technologies also plan to develop the capabilities to deploy, manage, and update AI models on Aramco Digital's edge AI devices.

Global

QCOM

'Qualcomm And Aramco Digital To Drive Industry Transformation Through Commercialization Of Advanced Edge AI For Industrial IoT'

EXOZ

eXoZymes shares are trading higher following Q4 reported financial results.

TZUP

Thumzup Media shares are trading higher after the company announced the expansion of its capital strategy by establishing a bitcoin-backed credit facility to provide access to non-dilutive capital.

ESOA

Energy Services of America shares are trading lower after the company reported worse-than-expected Q2 financial results.

KinderCare Learning Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/klc/earnings">closing bell on Tuesday, May 13.</a>
Analysts expect the Lake Oswego, Oregon-based company to report quarterly earnings at 17 cents per share. KinderCare Learning projects to report quarterly revenue at $680.94 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 3, The Bear Cave released a short report on KinderCare, alleging the company is plagued by operational failures that could threaten its stock performance.
KinderCare Learning shares gained 2.7% to close at $13.53 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/KLC/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Joshua Chan maintained a Buy rating and cut the price target from $24 to $21 on April 15, 2025. This analyst has an accuracy rate of 65%.</li>
<li>BMO Capital analyst Jeffrey Silber maintained an Outperform rating and slashed the price target from $31 to $26 on March 24, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Goldman Sachs analyst George Tong maintained a Buy rating and cut the price target from $35 to $30 on March 21, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Baird analyst Jeffrey Mueler maintained an Outperform rating and lowered the price target from $30 to $25 on March 21, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Morgan Stanley analyst Toni Kaplan maintained an Overweight rating and cut the price target from $30 to $21 on March 21, 2025. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying KLC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13031735/image-132-1024x577.png" alt="" class="wp-image-912986" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13031735/image-132-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13031735/image-132-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13031735/image-132-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13031735/image-132.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45347009/top-2-tech-stocks-that-may-crash-in-q2">Top 2 Tech Stocks That May Crash In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Top Wall Street Forecasters Revamp KinderCare Learning Expectations Ahead Of Q1 Earnings

비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 현물 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">ETF</a>는 지난 4일 동안 각각 32억 6천만 달러와 7,443만 달러의 유입을 기록했다. 이러한 급격한 유입은 도널드 트럼프 대통령이 취임 연설에서 암호화폐 언급을 생략한 이후 암호화폐 시장의 변동성이 커졌음에도 불구하고 발생했다.
소소밸류(Sosovalue) 데이터에 따르면 기록적인 ETF로의 자금 유입은 1월 17일에 발생했다. 약 10억 8천만 달러가 다양한 비트코인 펀드로 유입되었다. 또한 1월 21일에는 8억 2,250만 달러가 유입되었다.
<h3 class="wp-block-heading">비트코인 ETF</h3>
<ul>
<li>블랙록의 iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>): 최대 순 유입액 6억 6,186만 달러 기록</li>
<li>그레이스케일의 Bitcoin Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>): 1억 3,639만 달러 유입</li>
<li>ARK 21Shares Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#NYSE">ARKB</a>): 851만 달러 유입</li>
<li>Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>): 697만 달러 유입</li>
</ul>
이러한 추세와는 다르게 Bitwise의 Bitcoin ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>)에서는 이날 1,741만 달러의 자금이 유출되었다.
비트코인 현물 ETF는 총 1,359억 달러의 순자산 가치를 관리하고 있으며, 비트코인 전체 시장 가치의 약 5.88%에 해당하는 금액이다.
<h3 class="wp-block-heading">이더리움 ETF</h3>
<ul>
<li>블랙록의 iShares Ethereum Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>): 최대 순 유입액 5,631만 달러 기록</li>
<li>그레이스케일의 Ethereum Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETH#NYSE">ETH</a>): 1,249만 달러 유입</li>
<li>VanEck Ethereum ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ETHV#BATS">ETHV</a>): 365만 달러 유입</li>
<li>Fidelity의 Ethereum Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>): 332만 달러 유입</li>
</ul>
현재 9개의 이더리움 현물 ETF가 120억 7천만 달러의 자산을 관리하고 있으며, 이는 이더리움 시가총액의 약 3%에 해당한다.
트럼프 대통령이 취임 연설에서 암호화폐에 대한 언급을 자제하면서 비트코인은 연설 전 106,000달러에서 연설 중 101,000달러까지 하락했고, 현재 104,000달러를 기록하고 있다.
솔라나 역시 압박을 받아 사상 최고치에서 거의 10% 하락했다. 투자자들은 암호화폐의 미래에 대한 장기적인 비전에 베팅하고 이를 암호화폐 세계로 진입할 기회로 삼고 있을 수 있다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

VanEck Ethereum ETF VanEck Ethereum ETF

뉴스

에 대한 최신 뉴스 VanEck Ethereum ETF VanEck Ethereum ETF (BATS:ETHV)

목요일, 1월 23, 2025

뉴스

파트너 / 기고자

벤징가 글로벌